Insulin Pumps, Continuous Glucose Monitoring, Closed Loop Insulin Delivery Systems and

Notice Information

Get alerts for notices like these

Notice Title

Insulin Pumps, Continuous Glucose Monitoring, Closed Loop Insulin Delivery Systems and

Notice Description

In January 2022 NHS Supply Chain launched a non-exclusive Framework Agreement for supply to NHS Supply Chain customer base of Insulin Pumps Continuous Glucose Monitoring Closed Loop Insulin Delivery Systems and Associated Products. The Framework Agreement provides one ordering platform for all technologies, the objective to award broadly across the Framework Agreement to ensure continuity of supply for all key product areas and to also allow optimisation opportunities to be identified. In accordance with Section 3 of the ITT that was published in 2021, NHS Supply Chain has taken the decision to open the Framework Agreement to new Applicants to ensure the Framework Agreement continues to offer the broadest possible range of products to the NHS, as well as ensuring any new technologies and innovations in this product area are made available via the Framework Agreement. Applicants successfully awarded to the Framework Agreement during this Agile Tender will be awarded with the incumbent suppliers who were awarded to the Framework Agreement following the previous tendering exercise (Contract Award Notice reference: 2022/S 000-000260 which can be viewed at: https://www.gov.uk/find-tender).This agreement is for the supply of Insulin Pumps, Continuous Glucose Monitoring (CGM) devices, Applications or software to enable the function of Closed Loop Insulin Delivery Systems and also for the dedicated consumables and accessories for the products listed above. The Framework Agreement was launched in January 2022 with an initial term of 24 months with an option to extend incrementally for up to a total period of 48 months. Applicants successfully awarded to the Framework Agreement during this Agile Tender will therefore be awarded for an initial period of 12 months, with an option to extend incrementally for up to a total period of 36 months. It is anticipated that in the first 12 months of the Framework Agreement the value of the purchases will be circa PS20,000,000. For the full 36 month term (if extended) the anticipated value is circa PS75,000,000. These values are approximate only and are based on the most recent historical usage information, with a forecasted level of growth. The values provided are for guidance only and are not a guarantee of business or volumes to be purchased from any Supplier.

Lot Information

Insulin Pumps

This lot is for Standalone Insulin Pumps and also Tethered Insulin Pumps, Patch Insulin Pumps, Tethered Pump with Integrated Continuous Glucose Monitor, Patch Pumps with Integrated Continuous Glucose Monitor, Tethered Pump with Integrated Continuous Glucose Monitor and Algorithm. This Lot also includes, but is not limited to; Insulin subcutaneous infusion set Tubes Cannula's Needle cartridges Handsets Insertion Devices Adaptors Batteries Carry Cases Belts Remotes Sensors Finger Prickers Battery caps Resevoirs USB Adapters Clips Luer Locks Dressings Pouches Service packs Any other option or accessory used with or to configure the pumps. Additional information: Anticipated expenditure will be circa PS9,000,000 for the two years of this framework agreement, this is approximate and may vary depending on the requirements of bodies purchasing under the agreement. For the full 36 month term (if extended) the anticipated value is circa PS27,000,000. These values are approximate, based on historical usage information, with a forecasted level of growth.